Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
15.77
+0.46 (3.00%)
At close: Jun 15, 2026, 4:00 PM EDT
15.79
+0.02 (0.13%)
Pre-market: Jun 16, 2026, 7:38 AM EDT

Sarepta Therapeutics Stock Forecast

Stock Price Forecast

According to 24 analysts polled by S&P Global, Sarepta Therapeutics stock has a consensus rating of "Hold" and an average price target of $22. The average 1-year stock price forecast is 39.51% higher than the current stock price, while the lowest is $5.00 (-68.29%) and the highest is $38 (+140.96%).

Price Target: $22 (+39.51%)
Analyst Consensus: Hold
TargetLowAverageMedianHigh
Price$5.00$22$20$38
Change-68.29%+39.51%+26.82%+140.96%

Analyst Ratings

The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy777786
Buy000000
Hold141413131213
Sell222222
Strong Sell333333
Total262625252524

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Hold
Maintains
$18$19
HoldMaintains$18$19+20.48%May 19, 2026
Evercore ISI
Evercore ISI
Hold
Maintains
$20$19
HoldMaintains$20$19+20.48%May 15, 2026
Wedbush
Wedbush
Buy
Maintains
$35
BuyMaintains$35+121.94%May 15, 2026
Barclays
Barclays
Hold
Reiterates
$20
HoldReiterates$20+26.82%May 13, 2026
H.C. Wainwright
H.C. Wainwright
Sell
Reiterates
$5
SellReiterates$5-68.29%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.84B
from 2.20B
Decreased by -16.39%
Revenue Next Year
1.42B
from 1.84B
Decreased by -22.53%
EPS This Year
4.83
from -5.05
EPS Next Year
2.73
from 4.83
Decreased by -43.57%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
701.89M933.01M1.24B1.90B2.20B1.84B
Revenue Growth
29.96%32.93%33.26%52.97%15.58%-16.39%
Gross Profit
-160.24M-84.07M215.61M778.36M-163.43M1.47B
Gross Margin
-22.83%-9.01%17.34%40.92%-7.43%80.18%
Operating Income
-443.61M-536.20M-267.82M218.08M-657.77M475.31M
Net Income
-418.78M-703.49M-535.98M235.24M-713.41M415.13M
EPS
-----5.054.83
Forward PE
---15.4790.123.26
Free Cash Flow
-8.70M-54.65M-330.11M-432.21M95.92M2.50M
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High2.1B
Avg1.8B
Low1.7B

Revenue Growth

Revenue Growth202620272028
High
-6.5%
Avg
-16.4%
Low
-22.8%

EPS Forecast

EPS202620272028
High6.30
Avg4.83
Low3.45

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-